PARN

Across TCGA pan-cancer cohorts, PARN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARN data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PARN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PARN expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where PARN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.823	0.299	.002	27	view →
CCRCC	DFS	Tertile	III,IV	0.283	0.742	.002	19	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	8	view →
LSCC	DFS	Median	II,III,IV	0.851	0.553	.015	6	view →
PDAC	OS	Tertile	III,IV	1.000	0.460	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARN–LUAD (OS)

Open the LUAD breakdown →